In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
The Lancet Respiratory Medicine staged a debate between proponents and opponents of pan-TB regimens to tackle the current suboptimal worldwide management of TB resistance.
The National Tuberculosis Controllers Association and the Centers for Disease Control and Prevention have released updated guidelines for the treatment of latent tuberculosis infection.
A short, 9-month regimen of normal dose moxifloxacin maintained good effectiveness up to 24 months after therapy cessation in patients with rifampicin-resistant tuberculosis.
Daily doses of 10 to 15 mg/kg isoniazid demonstrated similar activity against tuberculosis (TB) strains with inhA mutations as 5 mg/kg doses against drug-sensitive strains.
Treatment with 4 months of rifampin for latent tuberculosis infection was associated with higher adherence, lower costs, and lower risk for severe hepatoxicity compared with 9 months of isoniazid.
